Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral thera
- PDF / 1,296,399 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 45 Downloads / 148 Views
RESEARCH ARTICLE
Open Access
Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct‑acting antiviral therapy Supachaya Sriphoosanaphan1,2, Kessarin Thanapirom1,2,3, Sirinporn Suksawatamnuay1,2,3, Panarat Thaimai1, Sukanya Sittisomwong1, Kanokwan Sonsiri1, Nunthiya Srisoonthorn2, Nicha Teeratorn1, Nattaporn Tanpowpong4, Bundit Chaopathomkul4, Sombat Treeprasertsuk1, Yong Poovorawan5 and Piyawat Komolmit1,2,3*
Abstract Background: Vitamin D (VD) is important in hepatic fibrogenesis in animal models and human studies. VD deficiency is associated with liver fibrosis progression. Metabolic dysfunction of the liver, as an intermediate organ for VD metabolism, contributes partly to this deficiency. We hypothesized that improving hepatic fibrosis and inflammation in chronic hepatitis C (CHC) patients after eradication with direct-acting antivirals (DAA) would increase 25-hydroxyVD [25(OH)VD] levels. Methods: Eighty CHC patients (17 chronic hepatitis, and 63 cirrhosis) were enrolled. Baseline characteristics, hepatitis C viral load (VL), genotypes, liver enzymes and liver stiffness measurements (LSM) were assessed at baseline. Blood samples for 25(OH)VD and the procollagen type III N-terminal peptide (P3NP) were collected at baseline, 24 and 48 weeks. LSMs were re-evaluated at 48 weeks. Serum 25(OH)VD levels
Data Loading...
